Could a worm enzyme soothe diabetic nerve damage?
NCT ID NCT07475065
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether an oral supplement called DLBS1033 (made from earthworm proteins) can reduce nerve damage symptoms in adults with diabetic polyneuropathy. Thirty-four people with type 2 diabetes will receive either the supplement or a placebo for 28 days, alongside standard care. Researchers will measure changes in neuropathy severity, inflammation, and nerve growth factors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DLBS1033 (lumbrokinase)
What this could lead to
If it works, this could point toward a new add-on treatment to ease nerve pain and improve nerve health in people with diabetic polyneuropathy.
What could go wrong
This is a small, early-phase trial with only 34 participants and a short 28-day treatment period. Results may not apply to everyone, and the supplement may not prove effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Moewardi Regional General Hospital
Surakarta, Central Java, 57143, Indonesia
Contact Phone: •••-•••-•••• Email: •••••@•••••